Review Article

Can We Find Better Bronchodilators to Relieve Asthma Symptoms?

Elizabeth A. Townsend, Peter D. Yim, George Gallos, and Charles W. Emala

Department of Anesthesiology, College of Physicians and Surgeons, Columbia University, 650 W 168th Street, New York, NY 10032, USA

Correspondence should be addressed to Charles W. Emala, cwe5@columbia.edu

Received 26 July 2012; Accepted 5 September 2012

Academic Editor: Yassine Amrani

Copyright © 2012 Elizabeth A. Townsend et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Bronchodilators are the first line therapy during acute asthmatic exacerbations to reverse airway obstruction primarily by relaxing airway smooth muscle. Only three categories of bronchodilators exist in clinical practice: β -adrenergic agonists, anticholinergics, and methylxanthines. Each of these categories have specific drugs dating back to the early 20th century, raising the question of whether or not we can find better bronchodilators. While caffeine, theophylline, atropine, and epinephrine were the first generations of therapeutics in each of these drug classes, there is no question that improvements have been made in the bronchodilators in each of these classes. In the following editorial, we will briefly describe new classes of potential bronchodilators including: novel PDE inhibitors, natural phytotherapeutics, bitter taste receptor ligands, and chloride channel modulators, which have the potential to be used alone or in combination with existing bronchodilators to reverse acute airway obstruction in the future.

1. Novel PDE Inhibitors

Caffeine and theophylline are two methylxanthines that have been used to treat asthma, although their exact mechanisms of action are still unknown [1, 2]. The bronchodilating property of theophylline is largely attributed to inhibition of phosphodiesterase (PDE) activity or the release of catecholamines, thereby increasing cAMP in airway smooth muscle [3]. In use since the 1930s, lack of specificity, a narrow therapeutic window, and negative side effects, plus the development of inhaled glucocorticoids, and short- and long-acting β_2 -agonists have decreased the clinical utility of theophylline [1, 4, 5]. However, the identification of airway-specific PDE4 subtypes and subsequent development of PDE4-selective inhibitors have resurrected this avenue as novel bronchodilators.

The newest PDE4 inhibitor approved for use in respiratory disease is roflumilast (Daxas) [6, 7]. In patients with COPD, roflumilast has shown significant improvement of FEV1 when taken in conjunction with long-acting β_2 -agonists or muscarinic antagonists [8]. In preclinical studies,

administration of selective PDE4 inhibitors prevented bronchial hyperresponsiveness (BHR) in allergic mice, an *in vivo* model for asthma [9, 10]. Although no PDE4-selective inhibitor is currently approved for the treatment of asthma in the United States, similar studies showed that administration of PDE4 inhibitors attenuated BHR in patients with allergic asthma [11–13]. With improved specificity for PDE4 subtypes, PDE4-selective inhibitors (roflumilast, CDP840, MK-0359), have decreased side effects compared to theophylline although the therapeutic window is still narrow and still produces systemic effects due to oral administration. Development of inhaled PDE4-selective inhibitors has shown potential in reducing early- and late-phase asthmatic responses in mild allergic asthmatics [14]. Whether or not these improvements in FEV1 are due to bronchodilation of airway smooth muscle or anti-inflammatory effects are yet to be determined; however, inhalation will likely reduce plasma levels of drug and decrease side effects associated with oral delivery. Further work on developing PDE4 subtype-specific inhibitors (A–D) or combining various PDE isoform inhibitors (i.e., PDE1, 3, 7 with PDE4

inhibitors) [5] may increase the efficacy of targeting this signaling pathway in treating asthma, providing a new application for a longstanding bronchodilator.

2. Natural Phytotherapeutics

Of note, one PDE4-selective inhibitor, quercetin, is a naturally occurring flavonol found in fruits, vegetables, and tea leaves. Retrospective studies have shown increasing numbers of asthmatics self-treat their symptoms with herbal remedies [15, 16]. In many cases, the exact mechanisms of action of these natural botanicals are unknown; however recent work has focused on identifying the active constituents of herbal remedies and elucidating the signaling pathways involved in acute bronchodilation. Given the advances in PDE inhibition and the natural origin of many methylxanthines, many of these natural phytotherapies may possess PDE inhibitory action.

Recently, natural plant products have received accolades for the treatment of cough, respiratory infection, and bronchospasm [17]. It is estimated that 10%–42% of asthmatics use herbal therapies to self-treat their asthma symptoms [16, 18]; however the efficacy and safety of most herbal therapies have not been scientifically evaluated [19]. The exact mechanism of action of most of these agents is unclear but may involve direct effects on airway smooth muscle, airway epithelium, airway nerves, inflammatory cytokines, and immune cells. Moreover, the formulations of these herbal compounds are made up of many individual bioactive compounds. As such, it is important to define both the positive and potential negative impacts of these individual compounds on the airway as well as explore the interaction of herbal therapies with existing asthma therapies (corticosteroids and β -agonists).

Extensive preclinical, animal, and human studies have demonstrated that antiasthma simplified herbal medicine intervention (ASHMI), an extract of 3 plants *Ganoderma lucidum* (Ling-Zhi), *Sophora flavescens* (Ku-Shen) and *Glycyrrhiza uralensis* (Gan-Cao), reduces lung inflammation, airway remodeling, and airway smooth muscle hyperresponsiveness [20–22]. A blinded randomized trial in 91 subjects with moderate to severe allergic asthma demonstrated that 4 weeks of oral ASHMI were nearly equivalent to oral prednisone in the improvement in FEV1, peak flows, serum IgE levels, and eosinophilia [23]. The safety and tolerance of oral ASHMI were confirmed in a dose escalation study [21]. These clinical studies were followed by a series of preclinical studies that sought to identify the mechanism(s) involved in the improvement of symptom and inflammatory profiles. Both chronic and acute beneficial effects of ASHMI were demonstrated on mouse lung inflammation and responsiveness. Six weeks of oral administration of ASHMI reduced inflammation and *in vivo* responses to acetylcholine [20, 22, 24]. Acute treatment of isolated tracheal rings with ASHMI from naïve or ovalbumin sensitized mice demonstrated reduced acetylcholine-induced contractions in *ex vivo* organ bath experiments [22]. A possible mechanism for these acute effects was elucidated in human airway

smooth muscle cells that liberated prostaglandins in response to ASHMI [22], which could mediate relaxation through activation of G_s -coupled EP2 or EP4 receptors [25]. Current research is focused on identifying the specific purified chemical constituents of ASHMI that mediate these chronic anti-inflammatory effects and acute airway smooth muscle relaxant effects.

Although PGE₂ relaxes airway smooth muscle in many species and benefits of inhaled PGE₂ have been shown in asthmatics, a specific agonist for the EP2 receptor failed to show benefit in human trials [26]. However, newer studies suggest that targeting the EP4 receptor in human airway smooth muscle may be an alternative therapeutic target in patients with asthma [27].

3. Bitter Tastants

Another potential therapeutic target in the treatment of bronchoconstrictive disease involves the bitter taste receptor family (TAS2R). Recently, both qRT-PCR analysis and immunofluorescence microscopy of human airway smooth muscle (ASM) cells revealed robust expression of several members of this G-protein-coupled receptor family (TASR-10, -14, and -31) and showed increases in intracellular calcium ($[Ca^{2+}]_i$) in response to subsequent exposure to bitter tastants, the agonists to these receptor subtypes [28]. Despite increasing ASM $[Ca^{2+}]_i$ via the same pathway ($G\beta\gamma \rightarrow PLC\beta \rightarrow IP_3R$) shared by the classical contractile agonist acetylcholine, this group paradoxically found activation of TAS2R in ASM leads to a profound degree of ASM bronchodilation in both isolated ASM preparations as well as *in vivo* models of induced airway responsiveness. Interestingly, the magnitude of bronchodilation achieved by high-dose TAS2R agonists in many of these studies rivaled maximal β -agonist treatments and mechanistically was found to be cAMP- and PKC-independent. This group has recently extended this observation to show that in relevant models of β_2 -adrenoceptor desensitization, chloroquine-mediated TAS2R activation in ASM retains its pro-bronchodilatory effects, a finding of considerable clinical relevance given the well-described concern of β -agonist tachyphylaxis that occurs with repetitive β -agonism [29]. Yet, it should be noted that TAS2R activation in ASM can lead to desensitization via a GRK-mediated, β -arrestin pathway, which may limit its therapeutic usefulness as it is seen currently with β -adrenoceptor agonists [30].

Mechanistically, TAS2R activation in ASM is thought to achieve relaxation via a localized $[Ca^{2+}]$ -dependent activation of the large conductance Ca^{2+} -activated K^+ channel (BK_{Ca}) leading to membrane hyperpolarization. While other investigators have challenged the notion that bitter tastant-mediated ASM relaxation is BK_{Ca} -dependent [31], the evidence in human ASM suggests at least a partial role of the BK_{Ca} channel in what is likely a novel, multimodal mechanism leading to ASM relaxation [32]. The possibility of TAS2R activation in ASM (in the context of localized calcium release) leading to non- BK_{Ca} -mediated ASM relaxation via yet undescribed pathways is another exciting prospect behind

TABLE 1: Summary of benefits and limitations of novel bronchodilators.

Drug class	Benefits	Limitations
β -agonists	Rapid airway relaxation Selective for β_2 -AR; decreased systemic effects	Receptor desensitization Receptor downregulation Refractory bronchoconstriction Asthma-related death
PDE inhibitors	Increase cAMP generated endogenously Enhance β_2 -AR effects Selectivity for subtypes specific to lung	Oral delivery Complex dosing and metabolism Systemic side effects Potential adenylyl cyclase and/or β_2 -AR desensitization
Phytotherapeutics	Airway relaxation Acute and chronic effects Reduces inflammation and remodeling Increased patient compliance	Mechanisms of action are not clearly defined Potential interaction with other drugs Difficulty standardizing source and dosing
Bitter tastants	Novel target—may augment traditional therapies due to cAMP-independence	Mechanisms of action are not clearly defined
Chloride channel modulators	Novel target—may augment traditional therapies May address neuronal components of airway tone	Mechanisms of action are not clearly defined Method of delivery Interaction with airway epithelium (mucous production) Systemic side effects

this work that may uncover other potent targets to facilitate relaxation not susceptible to GPCR tachyphylaxis.

4. Chloride Channel Modulators

Chloride channels are expressed on airway smooth muscle and have been shown to effect airway smooth muscle force [33] and cell length [34]. In 2005, Hirota et al., described attenuation of acetylcholine-induced contractions in ASM subsequent to calcium-activated chloride channel antagonism [33]. Additionally, activation of the ligand-gated chloride channel, GABA_A, relaxed airway smooth muscle precontracted with the tachykinin, substance P [35]. In 2011, another ligand-gated chloride channel, the glycine receptor, was shown to relax airway smooth muscle contracted with a selective neurokinin 2 receptor agonist [36]. These and other studies have led to the understanding that chloride channels may play a significant role in the airway smooth muscle contraction and relaxation mechanisms.

Calcium-activated chloride channels have been described functionally; however, the true molecular identity of calcium-activated chloride channels have only recently been identified as belonging to the ANO or TMEM16 receptor family. The TMEM16 receptors are membrane proteins with 8 transmembrane domains shown to allow chloride flux in the presence of increasing calcium while possessing voltage sensitive activity. TMEM16A mRNA expression has been described in airway smooth muscle [37] and its function in other cell types has been described as contributing to membrane depolarization during calcium increases [38]. It has been hypothesized that acetylcholine- and caffeine-mediated release of calcium from the sarcoplasmic reticulum (SR) stimulates chloride efflux from the cell, leading to depolarization of the plasma membrane. Force studies in *ex vivo* airway smooth muscle preparations examining

the effects of chloride channel antagonists, 5-nitro-2-(3-phenylpropylamino)benzoic acid (NPPB), and niflumic acid (NFA), showed a large attenuation of acetylcholine-induced contraction by NPPB while NFA failed to have an effect. In contrast, caffeine-induced contractions were inhibited by both NFA and NPPB [33]. The differential effects of these chloride channel antagonists may be due to the effects on calcium-activated chloride channels located on the SR versus the plasma membrane. Recently, members of the TMEM family were shown to be expressed on various intracellular compartments and not exclusively on the plasma membrane [39]. A possible mechanism of attenuated force generation in airway smooth muscle by calcium-activated chloride channel antagonism may be inhibition of chloride ion efflux during contractile agonist stimulus.

Ligand-gated chloride channels have been well described in the central nervous system with two families dominating the role as inhibitory inputs, GABA_A, and glycine receptor channels. Both GABA_A and glycine receptors are expressed in ASM and possess functional roles in the modulation of airway smooth muscle tone generation [35, 36]. This inhibitory effect on ASM contraction may be attributed to a relative hyperpolarization of the membrane potential after it has surpassed the chloride reversal potential following exposure to a contractile stimulus. This opening of the chloride channels causes an influx of chloride ions leading to a relative membrane hyperpolarization, eliminating, or attenuating the electromechanical component of contraction. Additional studies have described the importance of specific GABA_A receptor subunits. GABA_A channels containing $\alpha 4$ or $\alpha 5$ subunits can be selectively targeted in airway smooth muscle resulting in effects on membrane potential and airway tone [40]. Pharmacotherapies that are not GABA_A subunit selective, such as the general anesthetic, propofol, have bronchodilatory capabilities [41]. Increased airway smooth muscle specificity will determine the viability

of GABA_A-related therapies as bronchorelaxants. GABA_A function in airway smooth muscle has been studied in both rodent and human *ex vivo* models, as well as *in vivo* rodent models [42, 43], producing strong evidence that this channel, once thought to be exclusively neuronally expressed, may have direct effects on airway tone.

In the last ten years, the existence of chloride channels in airway smooth muscle has been confirmed yet our current understanding of their mechanistic and functional roles remains incomplete. Although poorly mechanistically understood [44, 45] manipulation of chloride channels still remains a viable avenue of further research in the discovery of novel bronchodilators. Continued research will uncover the exact mechanisms that dictate the role for chloride channels in the balance of contraction and relaxation in the airway.

While bronchodilators will likely continue to be a mainstay of asthma therapy far into the future, the classical relaxant, β -agonist, is not without limitations. Receptor desensitization, β -agonist insensitivity, β -agonist refractory bronchoconstriction, and even death are all risks associated with prolonged use of traditional β -agonists. As such, it is important to continually investigate new therapeutics for the treatment of asthma; keeping in mind that acute bronchodilation is the first line therapy during an asthmatic episode. Here we have illustrated 4 novel potential therapeutics that show functional bronchodilatory properties in the airway owing to a variety of mechanisms. These novel compounds may augment existing β -agonist relaxant effects as in the case of PDE inhibitors or provide complementary avenues for relaxation when combined with current therapies. Table 1 summarizes beneficial aspects of traditional β -agonists and these novel therapeutics as well as illustrating current limitations to implementing these novel bronchodilators. Interestingly, compounds that transiently elevate $[Ca^{2+}]_i$ such as phytotherapeutics, bitter taste ligands, GABA_A receptor ligands, and chloride channel antagonists subsequently lead to functional relaxation of airways. This is counterintuitive in the face of decades of research closely linking global cellular calcium and smooth muscle contraction thus necessitating a broader understanding of complex calcium dynamics within cellular microdomains. While the mechanism of action of these potential therapeutics is still under investigation, they open the door for assessing new therapeutics and mechanisms leading to bronchodilation.

References

- [1] D. Spina, "PDE4 inhibitors: current status," *British Journal of Pharmacology*, vol. 155, no. 3, pp. 308–315, 2008.
- [2] C. Schudt, A. Hatzelmann, R. Beume, and H. Tenor, "Phosphodiesterase inhibitors: history of pharmacology," *Handbook of Experimental Pharmacology*, vol. 204, pp. 1–46, 2011.
- [3] C. K. Billington, O. O. Ojo, R. B. Penn, and S. Ito, "cAMP regulation of airway smooth muscle function," *Pulmonary Pharmacology & Therapeutics*. In press.
- [4] C. P. Page and D. Spina, "Selective PDE inhibitors as novel treatments for respiratory diseases," *Current Opinion in Pharmacology*, vol. 12, no. 3, pp. 275–286, 2012.
- [5] M. A. Giembycz, "Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors," *Current Opinion in Pharmacology*, vol. 5, no. 3, pp. 238–244, 2005.
- [6] M. A. Giembycz and S. K. Field, "Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD," *Drug Design, Development and Therapy*, vol. 4, pp. 147–158, 2010.
- [7] N. J. Gross, M. A. Giembycz, and S. I. Rennard, "Treatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor," *COPD*, vol. 7, no. 2, pp. 141–153, 2010.
- [8] L. M. Fabbri, P. M. Calverley, J. L. Izquierdo-Alonso et al., "Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials," *The Lancet*, vol. 374, no. 9691, pp. 695–703, 2009.
- [9] T. T. Kung, Y. Crawley, B. Luo, S. Young, W. Kreutner, and R. W. Chapman, "Inhibition of pulmonary eosinophilia and airway hyperresponsiveness in allergic mice by rolapram: Involvement of endogenously released corticosterone and catecholamines," *British Journal of Pharmacology*, vol. 130, no. 2, pp. 457–463, 2000.
- [10] A. Kanehiro, T. Ikemura, M. J. Mäkelä et al., "Inhibition of phosphodiesterase 4 attenuates airway hyperresponsiveness and airway inflammation in a model of secondary allergen challenge," *American Journal of Respiratory and Critical Care Medicine*, vol. 163, no. 1, pp. 173–184, 2001.
- [11] P. L. Harbinson, D. MacLeod, R. Hawksworth et al., "The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects," *European Respiratory Journal*, vol. 10, no. 5, pp. 1008–1014, 1997.
- [12] E. Van Schalkwyk, K. Strydom, Z. Williams et al., "Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions," *Journal of Allergy and Clinical Immunology*, vol. 116, no. 2, pp. 292–298, 2005.
- [13] S. Lu, N. Liu, S. B. Dass, T. F. Reiss, and B. A. Knorr, "Randomized, placebo-controlled study of a selective PDE4 inhibitor in the treatment of asthma," *Respiratory Medicine*, vol. 103, no. 3, pp. 342–347, 2009.
- [14] D. Singh, F. Petavy, A. J. Macdonald, A. L. Lazaar, and B. J. O'Connor, "The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma," *Respiratory Research*, vol. 11, article 26, 2010.
- [15] Y. N. Clement, "Herbal self-medication at primary health care facilities in Trinidad," *Journal of Alternative and Complementary Medicine*, vol. 15, no. 1, pp. 6–7, 2009.
- [16] J. O. Rivera, H. W. Hughes, and A. G. Stuart, "Herbals and asthma: usage patterns among a border population," *Annals of Pharmacotherapy*, vol. 38, no. 2, pp. 220–225, 2004.
- [17] B. B. Singh, R. Khorsan, S. P. Vinjamury, C. Der-Martirosian, A. Kizhakkeveetil, and T. M. Anderson, "Herbal treatments of asthma: a systematic review," *Journal of Asthma*, vol. 44, no. 9, pp. 685–698, 2007.
- [18] T. P. Ng, M. L. Wong, C. Y. Hong, K. T. C. Koh, and L. G. Goh, "The use of complementary and alternative medicine by asthma patients," *QJM*, vol. 96, no. 10, pp. 747–754, 2003.
- [19] L. Bielory, "The science of complementary and alternative medicine: the plural of anecdote is not evidence," *Annals of Allergy, Asthma and Immunology*, vol. 93, no. 2, pp. S1–S4, 2004.
- [20] P. J. Busse, B. Schofield, N. Birmingham et al., "The traditional Chinese herbal formula ASHMI inhibits allergic lung inflammation in antigen-sensitized and antigen-challenged

- aged mice," *Annals of Allergy, Asthma and Immunology*, vol. 104, no. 3, pp. 236–246, 2010.
- [21] K. Kelly-Pieper, S. P. Patil, P. Busse et al., "Safety and tolerability of an antiasthma herbal formula (ashmi) in adult subjects with asthma: a randomized, double-blinded, placebo-controlled, dose-escalation phase 1 study," *Journal of Alternative and Complementary Medicine*, vol. 15, no. 7, pp. 735–743, 2009.
 - [22] T. Zhang, K. Srivastava, M. C. Wen et al., "Pharmacology and immunological actions of a herbal medicine ASHMI on allergic asthma," *Phytotherapy Research*, vol. 24, no. 7, pp. 1047–1055, 2010.
 - [23] M. C. Wen, C. H. Wei, Z. Q. Hu et al., "Efficacy and tolerability of antiasthma herbal medicine intervention in adult patients with moderate-severe allergic asthma," *Journal of Allergy and Clinical Immunology*, vol. 116, no. 3, pp. 517–524, 2005.
 - [24] K. Srivastava, T. Zhang, N. Yang, H. Sampson, and X. M. Li, "Anti-asthma simplified herbal medicine intervention-induced long-lasting tolerance to allergen exposure in an asthma model is interferon- γ , but not transforming growth factor- β dependent," *Clinical and Experimental Allergy*, vol. 40, no. 11, pp. 1678–1688, 2010.
 - [25] Y. Sugimoto and S. Narumiya, "Prostaglandin E receptors," *Journal of Biological Chemistry*, vol. 282, no. 16, pp. 11613–11617, 2007.
 - [26] A. T. Nials, C. J. Vardey, L. H. Denyer et al., "AH13205, a selective prostanoid EP2-receptor agonist," *Cardiovascular Drug Reviews*, vol. 11, no. 2, pp. 165–179, 1993.
 - [27] J. Buckley, M. A. Birrell, S. A. Maher, A. T. Nials, D. L. Clarke, and M. G. Belvisi, "EP4 receptor as a new target for bronchodilator therapy," *Thorax*, vol. 66, no. 12, pp. 1029–1035, 2011.
 - [28] D. A. Deshpande, W. C. H. Wang, E. L. McIlmoyle et al., "Bitter taste receptors on airway smooth muscle bronchodilate by localized calcium signaling and reverse obstruction," *Nature Medicine*, vol. 16, no. 11, pp. 1299–1304, 2010.
 - [29] S. S. An, W. C. Wang, C. J. Koziol-White et al., "TAS2R activation promotes airway smooth muscle relaxation despite β 2-adrenergic receptor tachyphylaxis," *American Journal of Physiology*, vol. 303, no. 4, pp. L304–L311, 2012.
 - [30] K. S. Robinett, D. A. Deshpande, M. M. Malone, and S. B. Liggett, "Agonist-promoted homologous desensitization of human airway smooth muscle bitter taste receptors," *American Journal of Respiratory Cell and Molecular Biology*, vol. 45, no. 5, pp. 1069–1074, 2011.
 - [31] C. H. Zhang, C. Chen, L. M. Lifshitz, K. E. Fogarty, M. S. Zhu, and R. ZhuGe, "Activation of BK channels may not be required for bitter tastant-induced bronchodilation," *Nature Medicine*, vol. 18, no. 5, pp. 648–651, 2012.
 - [32] S. S. An, K. S. Robinett, D. A. Deshpande, W. C. Wang, and S. B. Liggett, "Reply to: activation of BK channels may not be required for bitter tastant-induced bronchodilation," *Nature Medicine*, vol. 18, no. 5, pp. 650–651, 2012.
 - [33] S. Hirota, N. Trimble, E. Pertens, and L. J. Janssen, "Intracellular Cl⁻ fluxes play a novel role in Ca²⁺ handling in airway smooth muscle," *American Journal of Physiology*, vol. 290, no. 6, pp. L1146–L1153, 2006.
 - [34] R. Zhuge, R. Bao, K. E. Fogarty, and L. M. Lifshitz, "Ca²⁺ sparks act as potent regulators of excitation-contraction coupling in airway smooth muscle," *Journal of Biological Chemistry*, vol. 285, no. 3, pp. 2203–2210, 2010.
 - [35] K. Mizuta, D. Xu, Y. Pan et al., "GABAA receptors are expressed and facilitate relaxation in airway smooth muscle," *American Journal of Physiology*, vol. 294, no. 6, pp. L1206–L1216, 2008.
 - [36] P. D. Yim, G. Gallos, D. Xu, Y. Zhang, and C. W. Emala, "Novel expression of a functional glycine receptor chloride channel that attenuates contraction in airway smooth muscle," *FASEB Journal*, vol. 25, no. 5, pp. 1706–1717, 2011.
 - [37] J. R. Rock, C. R. Futtner, and B. D. Harfe, "The transmembrane protein TMEM16A is required for normal development of the murine trachea," *Developmental Biology*, vol. 321, no. 1, pp. 141–149, 2008.
 - [38] F. Huang, J. R. Rock, B. D. Harfe et al., "Studies on expression and function of the TMEM16A calcium-activated chloride channel," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 106, no. 50, pp. 21413–21418, 2009.
 - [39] C. Duran, Z. Qu, A. O. Osunkoya, Y. Cui, and H. C. Hartzell, "ANO3–7 in the anoctamin/Tmem16 Cl⁻ channel family are intracellular proteins," *American Journal of Physiology*, vol. 302, no. 3, pp. C482–C493, 2012.
 - [40] G. Gallos, P. Yim, S. Chang et al., "Targeting the restricted alpha-subunit repertoire of airway smooth muscle GABAA receptors augments airway smooth muscle relaxation," *American Journal of Physiology*, vol. 302, no. 2, pp. L248–L256, 2012.
 - [41] R. Pizov, R. H. Brown, Y. S. Weiss et al., "Wheezing during induction of general anesthesia in patients with and without asthma: a randomized, blinded trial," *Anesthesiology*, vol. 82, no. 5, pp. 1111–1116, 1995.
 - [42] N. R. Gleason, G. Gallos, Y. Zhang, and C. W. Emala, "The GABAA agonist muscimol attenuates induced airway constriction in guinea pigs in vivo," *Journal of Applied Physiology*, vol. 106, no. 4, pp. 1257–1263, 2009.
 - [43] G. Gallos, N. R. Gleason, Y. Zhang et al., "Activation of endogenous GABAA channels on airway smooth muscle potentiates isoproterenol-mediated relaxation," *American Journal of Physiology*, vol. 295, no. 6, pp. L1040–L1047, 2008.
 - [44] L. J. Janssen, "Airway smooth muscle electrophysiology in a state of flux?" *American Journal of Physiology*, vol. 302, no. 8, pp. 730–732, 2012.
 - [45] G. Gallos, P. Yim, and C. W. Emala, "Chloride in airway smooth muscle: the ignored anion no longer?" *American Journal of Physiology*, vol. 302, no. 8, pp. L733–L735, 2012.